Temple, the longevity and preventive health venture backed by entrepreneur Deepinder Goyal acquired the London-based longevity platform Longevous, marking its expansion into the UK.
The acquisition represents Temple’s first major cross-border expansion, allowing the company to accelerate the deployment of its proactive health tracking, biological age assessment, and personalised wellness protocols across the UK and European markets.
Temple is a wearable health-tech startup founded by Goyal that is developing a small device worn on the side of the head, around the temple area.
It is designed to collect physiological signals fom the head and use them to provide information about the body’s functioning.
However, the device lacks scientific validation and is under test.
Longevous has established a footprint in the UK’s rapidly expanding longevity sector, focusing on biomarker analysis, preventative therapies, and lifestyle interventions designed to extend healthspan.
Longevous will continue to operate as part of Temple, while its founders, Dr Robert Mohr and Dr Avi Roy, will join Temple full-time.
Goyal said the acquisition would bring medical and scientific expertise into Temple as it prepares for launch.
"They bring in deep clinical expertise and publication experience to work alongside our in-house science team as we prepare for launch," Goyal said in a post announcing the deal.
Longevous brings Temple an existing medical practice and a team with experience in this area. Dr Robert Mohr, who will become Temple's Chief Medical Officer, is a board-certified physician with nearly two decades of clinical experience.
He moved from emergency medicine into evidence-based longevity medicine, with experience in preventive and precision medicine.
Dr Avi Roy will become Temple's Head of Science. He is an Oxford-trained biomedical scientist and has worked at the intersection of longevity research and business. He was also a research fellow at the University of Oxford's Centre for the Advancement of Sustainable Medical Innovation.
Reportedly, Temple plans to leverage local clinical partnerships, streamline regulatory pathways, and expand access to personalised health optimisation programmes.
